Fate Therapeutics, Inc. (FATE)
2.435
+0.10
(+4.51%)
USD |
NASDAQ |
Aug 24, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Enterprise Value : 193.81M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 193.81M |
| August 20, 2026 | 207.81M |
| August 19, 2026 | 231.15M |
| August 18, 2026 | 220.64M |
| August 17, 2026 | 227.65M |
| August 14, 2026 | 221.81M |
| August 13, 2026 | 215.98M |
| August 12, 2026 | 239.32M |
| August 11, 2026 | 241.65M |
| August 10, 2026 | 243.98M |
| August 07, 2026 | 248.65M |
| August 06, 2026 | 212.48M |
| August 05, 2026 | 225.31M |
| August 04, 2026 | 221.81M |
| August 03, 2026 | 213.64M |
| July 31, 2026 | 207.81M |
| July 30, 2026 | 214.81M |
| July 29, 2026 | 197.31M |
| July 28, 2026 | 192.64M |
| July 27, 2026 | 205.47M |
| July 24, 2026 | 203.14M |
| July 23, 2026 | 215.98M |
| July 22, 2026 | 222.98M |
| July 21, 2026 | 252.15M |
| July 20, 2026 | 248.07M |
| Date | Value |
|---|---|
| July 17, 2026 | 246.32M |
| July 16, 2026 | 240.48M |
| July 15, 2026 | 270.82M |
| July 14, 2026 | 270.82M |
| July 13, 2026 | 274.32M |
| July 10, 2026 | 283.66M |
| July 09, 2026 | 284.83M |
| July 08, 2026 | 263.82M |
| July 07, 2026 | 274.32M |
| July 06, 2026 | 270.82M |
| July 02, 2026 | 262.65M |
| July 01, 2026 | 274.32M |
| June 30, 2026 | 236.98M |
| June 29, 2026 | 183.35M |
| June 26, 2026 | 146.14M |
| June 25, 2026 | 119.40M |
| June 24, 2026 | 141.49M |
| June 23, 2026 | 153.11M |
| June 22, 2026 | 151.95M |
| June 18, 2026 | 144.98M |
| June 17, 2026 | 129.86M |
| June 16, 2026 | 122.88M |
| June 15, 2026 | 135.67M |
| June 12, 2026 | 141.49M |
| June 11, 2026 | 131.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 609.42M |
| Amgen, Inc. | 280.82B |
| Anika Therapeutics, Inc. | 278.32M |
| BioCryst Pharmaceuticals, Inc. | 2.921B |
| Imunon, Inc. | 8.633M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.16M |
| Revenue (Quarterly) | 2.082M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.2505 |
| Gross Profit Margin (Quarterly) | -33.53% |
| Profit Margin (Quarterly) | -1.45K% |
| Earnings Yield | -43.24% |
| Normalized Earnings Yield | -43.10 |